Latest Articles

Publication Date
Targeting TLR4 Attenuates Endometriosis Progression by Suppressing NF-κB/NLRP3 Inflammasome Activation and Angiogenesis.

Endometriosis is a chronic inflammatory disorder affecting approximately 10% of reproductive-age women, yet non-hormonal therapeutic options remain limited. This study investigates the role of the TLR4/NF-κB/NLRP3 inflammasome axis in endometriosis …

Published: May 6, 2026, midnight
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
Microbiota-metabolite axis in endometriosis: Pathogenic mechanisms and clinical implications.

Growing evidence highlights the role of microbiota, including those of the gut, reproductive tract, and endometrial tissue, as critical functional drivers in the pathogenesis of endometriosis (EM). Studies have revealed …

Published: April 25, 2026, midnight
Pathogenesis of Adenomyosis: An Integrated Review of Cellular Origins, Molecular Mechanisms, and Intersecting Diseases.

Adenomyosis is a prevalent disorder of the archimetra, historically conflated with endometriosis but possessing a unique pathobiological trajectory. This review synthesises current molecular evidence to propose a unified mechanistic framework …

Published: April 14, 2026, midnight
Clinical and endocrine effects of pharmacological therapy in endometriosis: a systematic review and meta-analysis.

Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …

Published: April 1, 2026, midnight
Efficacy of probiotic supplementation in reducing primary dysmenorrhea: a double-blinded randomized controlled trial.

Primary dysmenorrhea is painful menstruation in the absence of pelvic pathology, whereas secondary dysmenorrhea is menstrual pain attributable to an underlying pelvic disease (e.g., endometriosis). Nonsteroidal anti-inflammatory drugs (NSAIDs) are …

Published: March 17, 2026, midnight
Exosome-Enriched Hub Gene Networks Identify Diagnostic Biomarkers and Repurposable Therapeutic Targets in Endometriosis.

Endometriosis is a heterogeneous chronic inflammatory disorder associated with substantial diagnostic delay and limited therapeutic options, highlighting the need of robust non-invasive biomarkers and actionable molecular targets to complement existing …

Published: March 11, 2026, midnight
Lactoferrin as a Non-Hormonal Therapeutic Candidate for Endometriosis: Mechanisms and Future Directions.

The pathogenesis and progression of endometriosis may involve a complex combination of multiple factors, including chronic inflammation and oxidative stress. Hormonal therapy, the current standard for pharmacotherapy in endometriosis, causes …

Published: March 5, 2026, midnight
Knowledge of menopause-associated symptoms and non-hormonal strategies: an Italian survey on social media platforms.

we aimed to provide data collected in women who were active on social media platforms about menopause-associated symptoms and their impact, as well as resources, preferences and needs, with a …

Published: Feb. 23, 2026, midnight
2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia.

Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …

Published: Feb. 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!